<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02893228</url>
  </required_header>
  <id_info>
    <org_study_id>AMNCH-A-SIPPIB</org_study_id>
    <nct_id>NCT02893228</nct_id>
  </id_info>
  <brief_title>Does Saline Injection Around Phrenic Nerve Reduce Incidence of Diaphragmatic Paresis Following Interscalene Block?</brief_title>
  <official_title>Does Saline Injection Around Phrenic Nerve Reduce Incidence of Diaphragmatic Paresis Following Interscalene Block?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Adelaide and Meath Hospital, incorporating The National Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Adelaide and Meath Hospital, incorporating The National Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemi-diaphragmatic palsy is a common undesirable effect of interscalene block, with an
      incidence of up to 100%. Mechanism of palsy is thought to be related to spread of local
      anaesthetic anterior to the anterior scalene muscle. We hypothesize that by injecting saline
      in this anatomical location prior to performing an interscalene block the incidence of
      phrenic palsy will be reduced.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomised to either group S (saline group) or group C (conventional group)
      by computer generated random numbers and allocation will be enclosed in sealed envelope.
      Anaesthetist performing and/or supervising the block will be the only personnel who will be
      aware of the randomisation. Patients will be blinded to the study group. Intraoperative
      management of the case will be done by an anaesthetist blinded to the study group. Outcome
      measurements will be recorded by study observers blinded to the group allocation.

      ISB protocol Following written informed consent, the patient will have routine monitors
      attached (ECG, Pulse oximeter and non-invasive blood pressure). Intravenous access will be
      secured and patients will be placed in 45 degree head-up position for the block with head
      turned to the non-operative side. Intravenous sedation with Midazolam (2 mg) and fentanyl (50
      to 100 microgram) will be administered to all patients prior to the block. The ultrasound
      machine will be positioned on the side opposite to the block. Skin will be prepped with 2%
      Chlorhexidine (Chloraprep) following which the block will be performed under strict aseptic
      precautions with the anesthetist wearing a mask and sterile gloves. The high frequency linear
      probe (sonosite) will be aligned transversely across the neck at the interscalene level to
      identify C5 and C6 nerve roots. 2% lidocaine will be used for skin infiltration and &quot;stop
      before block&quot; performed prior to insertion of block needle. In plane posterior approach will
      be used with a 50 mm short bevel block needle (Braun) advanced through middle scalene muscle.
      Following this, the technique differs between the two groups.

      In group C, the needle tip will then be positioned between C5 and C6 nerve roots. At this
      location, 15 ml of 0.25% levobupivacaine will be injected in 5 ml increments with
      intermittent aspiration. The needle tip will not be repositioned unless the patient
      complaints of paraesthesia.

      In group S, at the same level chosen for interscalene block, needle tip will be positioned
      anterior to anterior scalene muscle. At this location 10 ml 0.9% saline will be injected.
      This will then be followed by repositioning of needle between roots of C5 and C6 where 15 ml
      of 0.25% levobupivacaine will be injected in 5 ml increments with intermittent aspiration.
      The needle tip will not be repositioned unless the patient complaints of paraesthesia.

      Intra-operative procedure

      Following performance of the block, all patients will receive protocolised general
      anaesthetic. Anaesthesia will be induced with 2-3 mg per kg of propofol, followed by
      rocuronium 0.6mg/kg for muscle relaxation. Anaesthesia will be maintained with inhaled
      sevoflurane (MAC 1 end tidal concentration) along with air and oxygen mixture to deliver an
      inspired oxygen concentration of 40%. Antibiotics will be given as per hospital protocol
      prior to incision. In the absence of contraindications, all patients will receive intravenous
      paracetamol 1g and parecoxib 40 mg as a part of multimodal analgesia regimen. All patients
      will also receive intravenous dexamethasone 8 mg and ondansetron 4mg for post-operative
      nausea and vomiting prophylaxis. Further doses of fentanyl in 25 microgram increments will be
      administered by the anaesthetist if the heart rate increases by more than 15% of baseline
      values obtained prior to induction. Patients will be reversed by suggamadex. If at least two
      twitches are present during TOF measurement 2 mg/kg dose will be administered. If less than 2
      twitches are present, 4 mg/kg dose will be administered.

      Post-operative procedure:

      Following transfer to recovery unit, if patient reported pain score by numerical rating score
      was &gt;3, morphine 2 mg increments will be given intravenously by the recovery staff. This will
      be repeated every 5 minutes till the pain score is &lt;4. In patients needing more than 10 mg of
      morphine in the recovery, anaesthetist will be requested to review the patient.
      Post-operatively, in the absence of contraindications, all patients will be prescribed
      regular paracetamol 1g, 6 hourly and celecoxib 200 mg, 12 hourly. For breakthrough pain,
      oxynorm 10 mg as needed once every 4 hours will be prescribed. Anti-emetics (ondansetron 4
      mg, 8 hourly and Cyclizine 50 mg, 8 hourly) will be prescribed for all patients to be
      administered as required. Patient will also be asked about presence or absence of subjective
      feeling of dypnoea and report satisfaction of overall anaesthetic management (numerical
      rating scale 0-10) prior to discharge from recovery.

      Diaphragm palsy and PFT assessment Diaphragm assessment and bed side spirometry will be done
      at two time points. First measurement (time point 1) will be done at the baseline as soon as
      the patient arrives in the induction room. This will be done prior to administration of any
      sedative agents or regional block. Second assessment (time point 2) will be done
      post-operatively once the patients are deemed to be ready for discharge from recovery back to
      the ward.

      For diaphragmatic paresis assessment, patients will be placed in supine position and
      curvilinear ultrasound probe (2-5 MHz) will be used. Diaphragm will be identified as
      hyperechoic line by subcostal approach using liver and spleen as acoustic windows. Patients
      will be requested to take deep breaths and M mode will be used to measure the excursion of
      diaphragm. Diaphragmatic paresis will be documented when there is more than 75% reduction in
      the excursion compared to baseline or if there was paradoxical movement of the diapragm.
      Bedside assessment will be done by radiologist blinded to the study group.

      Bedside spirometry assessments will be done with patients sitting up. They will be requested
      to make maximum inspiratory effort and blow as hard and fast in to the device. Best reading
      from three repeated measurements will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of diaphragmatic paresis recorded in the post-operative period identified by ultrasound assessment</measure>
    <time_frame>4 hours</time_frame>
    <description>Diaphragmatic paresis will be documented with greater than 75% reduction in excursion compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>4 hours</time_frame>
    <description>Forced expiratory volume in 1 second (FEV1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC</measure>
    <time_frame>4 hours</time_frame>
    <description>Forced vital capacity (FVC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEFR</measure>
    <time_frame>4 hours</time_frame>
    <description>Peak expiratory flow rate (PEFR) will be assessed and compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain control</measure>
    <time_frame>24 hours post-opertive</time_frame>
    <description>Intra-operative fentanyl consumption, post-operative morphine consumption in 24 hours, pain scores (numerical 1-10) on arrival in recovery and at 24 hours post operatively</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>4 hours</time_frame>
    <description>Patient satisfaction scores obtained prior to discharge from recovery will be obtained by numerical rating score 0-10</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Phrenic Nerve Palsy</condition>
  <arm_group>
    <arm_group_label>Group S (saline group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In plane posterior approach will be used with a 50mm short bevel block needle (Braun), advanced through the middle scalene muscle. At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected. This will be followed by repositioning of the needle between roots C5 and C6 where 20 ml of 0.25% levobupivicaine will be injected in 5ml increments with intermittent aspiration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (control group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In plane posterior approach will be used with a 50mm short bevel block needle (Braun), advanced through the middle scalene muscle. The needle tip will be positioned between roots C5 and C6 where 20 ml of 0.25% levobupivicaine will be injected in 5ml increments with intermittent aspiration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected.</description>
    <arm_group_label>Group S (saline group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine</intervention_name>
    <description>the needle tip will then be positioned between C5 and C6 nerve roots. At this location, 20 ml of 0.25% levobupivacaine will be injected in 5 ml increments with intermittent aspiration. The needle tip will not be repositioned unless the patient complaints of paraesthesia</description>
    <arm_group_label>Group S (saline group)</arm_group_label>
    <arm_group_label>Group C (control group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing surgery on shoulder, humerus, or clavicle

        Exclusion Criteria:

          -  Patient refusal

          -  Allergy to local anaesthesia

          -  Severe coagulopathy

          -  Contralateral phrenic nerve palsy

          -  Local infection

          -  Moderate to severe pulmonary dysfunction (GOLD II, II, IV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karthikeyan Srinivasan, MD., FCARCSI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Adelaide and Meathe Hospital, Incorporating National Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karthikeyan K Srinivasan, MD.,FCARCSI</last_name>
    <phone>014142653</phone>
    <email>k.srinivasan@amnch.ie</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lindi Snyman, MBBCh.,FCAI</last_name>
    <phone>014142653</phone>
    <email>lindisnyman@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Adelaide and Meath Hospital, Incorporating National Children Hospital</name>
      <address>
        <city>Tallagh</city>
        <state>Dublin 24</state>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <reference>
    <citation>Urmey WF, Talts KH, Sharrock NE. One hundred percent incidence of hemidiaphragmatic paresis associated with interscalene brachial plexus anesthesia as diagnosed by ultrasonography. Anesth Analg. 1991 Apr;72(4):498-503.</citation>
    <PMID>2006740</PMID>
  </reference>
  <reference>
    <citation>Urmey WF, Grossi P, Sharrock NE, Stanton J, Gloeggler PJ. Digital pressure during interscalene block is clinically ineffective in preventing anesthetic spread to the cervical plexus. Anesth Analg. 1996 Aug;83(2):366-70.</citation>
    <PMID>8694320</PMID>
  </reference>
  <reference>
    <citation>Urmey WF, McDonald M. Hemidiaphragmatic paresis during interscalene brachial plexus block: effects on pulmonary function and chest wall mechanics. Anesth Analg. 1992 Mar;74(3):352-7.</citation>
    <PMID>1539813</PMID>
  </reference>
  <reference>
    <citation>Cangiani LH, Rezende LA, Giancoli Neto A. Phrenic nerve block after interscalene brachial plexus block. Case report. Rev Bras Anestesiol. 2008 Mar-Apr;58(2):152-9. English, Portuguese.</citation>
    <PMID>19378533</PMID>
  </reference>
  <reference>
    <citation>Rau RH, Chan YL, Chuang HI, Cheng CR, Wong KL, Wu KH, Wei TT. Dyspnea resulting from phrenic nerve paralysis after interscalene brachial plexus block in an obese male--a case report. Acta Anaesthesiol Sin. 1997 Jun;35(2):113-8.</citation>
    <PMID>9293653</PMID>
  </reference>
  <reference>
    <citation>Wennike N, Thompson A. Interscalene block as a precipitant of respiratory dysfunction. Br J Hosp Med (Lond). 2012 Apr;73(4):227.</citation>
    <PMID>22585200</PMID>
  </reference>
  <reference>
    <citation>Sinha SK, Abrams JH, Barnett JT, Muller JG, Lahiri B, Bernstein BA, Weller RS. Decreasing the local anesthetic volume from 20 to 10 mL for ultrasound-guided interscalene block at the cricoid level does not reduce the incidence of hemidiaphragmatic paresis. Reg Anesth Pain Med. 2011 Jan-Feb;36(1):17-20.</citation>
    <PMID>21751435</PMID>
  </reference>
  <reference>
    <citation>Lee JH, Cho SH, Kim SH, Chae WS, Jin HC, Lee JS, Kim YI. Ropivacaine for ultrasound-guided interscalene block: 5 mL provides similar analgesia but less phrenic nerve paralysis than 10 mL. Can J Anaesth. 2011 Nov;58(11):1001-6. doi: 10.1007/s12630-011-9568-5. Epub 2011 Aug 20.</citation>
    <PMID>21858614</PMID>
  </reference>
  <reference>
    <citation>Palhais N, Brull R, Kern C, Jacot-Guillarmod A, Charmoy A, Farron A, Albrecht E. Extrafascial injection for interscalene brachial plexus block reduces respiratory complications compared with a conventional intrafascial injection: a randomized, controlled, double-blind trial. Br J Anaesth. 2016 Apr;116(4):531-7. doi: 10.1093/bja/aew028.</citation>
    <PMID>26994230</PMID>
  </reference>
  <reference>
    <citation>Stundner O, Meissnitzer M, Brummett CM, Moser S, Forstner R, Kok√∂fer A, Danninger T, Gerner P, Kirchmair L, Fritsch G. Comparison of tissue distribution, phrenic nerve involvement, and epidural spread in standard- vs low-volume ultrasound-guided interscalene plexus block using contrast magnetic resonance imaging: a randomized, controlled trial. Br J Anaesth. 2016 Mar;116(3):405-12. doi: 10.1093/bja/aev550.</citation>
    <PMID>26865133</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>September 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Adelaide and Meath Hospital, incorporating The National Children's Hospital</investigator_affiliation>
    <investigator_full_name>Karthikeyan Kallidaikurichi Srinivasan</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>forced expiratory volume in 1 second</keyword>
  <keyword>forced vital capacity</keyword>
  <keyword>peak expiratory flow rate</keyword>
  <keyword>interscalene block</keyword>
  <keyword>diaphragmatic paresis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paresis</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levobupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

